{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T05:34:49Z","timestamp":1770960889036,"version":"3.50.1"},"reference-count":13,"publisher":"American Society of Hematology","issue":"6","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2003,3,15]]},"abstract":"<jats:p>Antithymocyte globulin (ATG) has recently been popularized as an effective treatment in myelodysplastic syndrome (MDS). We treated 8 anemic MDS patients (refractory anemia [RA] and refractory anemia with excess blasts [RAEB-1]) with ATG (40 mg\/kg\/d for 4 days) and prednisone in a phase 2 trial. The study was stopped early according to a preset termination rule because of lack of efficacy. There were no salutary responses. Toxicities included serum sickness (in all patients), transient neutropenia and thrombocytopenia, diarrhea, vomiting, and syncope with a generalized seizure. At least 3 patients had the HLA-DR15 (DR2) allele. We conclude that the risk-benefit ratio of ATG in an unselected population of MDS patients may be unfavorable, and more work is needed to define the subset of patients who will respond to ATG before its widespread use can be recommended.<\/jats:p>","DOI":"10.1182\/blood-2002-09-2867","type":"journal-article","created":{"date-parts":[[2003,2,27]],"date-time":"2003-02-27T18:28:53Z","timestamp":1046370533000},"page":"2156-2158","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":78,"title":["Antithymocyte globulin has limited efficacy and substantial toxicity in unselected anemic patients with myelodysplastic syndrome"],"prefix":"10.1182","volume":"101","author":[{"given":"David P.","family":"Steensma","sequence":"first","affiliation":[{"name":"From the Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN; Tissue Typing Laboratory, Division of Transfusion Medicine, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN; and Division of Biostatistics, Department of Health Sciences Research, Mayo Clinic, Rochester, MN."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Dispenzieri","sequence":"additional","affiliation":[{"name":"From the Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN; Tissue Typing Laboratory, Division of Transfusion Medicine, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN; and Division of Biostatistics, Department of Health Sciences Research, Mayo Clinic, Rochester, MN."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. Breanndan","family":"Moore","sequence":"additional","affiliation":[{"name":"From the Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN; Tissue Typing Laboratory, Division of Transfusion Medicine, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN; and Division of Biostatistics, Department of Health Sciences Research, Mayo Clinic, Rochester, MN."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georgene","family":"Schroeder","sequence":"additional","affiliation":[{"name":"From the Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN; Tissue Typing Laboratory, Division of Transfusion Medicine, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN; and Division of Biostatistics, Department of Health Sciences Research, Mayo Clinic, Rochester, MN."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayalew","family":"Tefferi","sequence":"additional","affiliation":[{"name":"From the Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN; Tissue Typing Laboratory, Division of Transfusion Medicine, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN; and Division of Biostatistics, Department of Health Sciences Research, Mayo Clinic, Rochester, MN."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"key":"2019111822504399100_B1","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1002\/ajh.2830410425","article-title":"T cell-mediated inhibition of erythropoiesis in myelodysplastic syndromes.","volume":"41","author":"Sugawara","year":"1992","journal-title":"Am J Hematol."},{"key":"2019111822504399100_B2","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S0889-8588(18)30329-0","article-title":"Immunologic abnormalities in myelodysplastic syndromes.","volume":"6","author":"Hamblin","year":"1992","journal-title":"Hematol Oncol Clin North Am."},{"key":"2019111822504399100_B3","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1046\/j.1365-2141.2001.02561.x","article-title":"Coincident myelodysplastic syndrome and T-cell large granular lymphocytic disease: clinical and pathophysiological features.","volume":"112","author":"Saunthararajah","year":"2001","journal-title":"Br J Haematol."},{"key":"2019111822504399100_B4","first-page":"353","article-title":"Action of antithymocyte globulin on normal human erythroid progenitor cell proliferation in vitro: erythropoietic growth-enhancing factors are released from marrow accessory cells.","volume":"107","author":"Mangan","year":"1986","journal-title":"J Lab Clin Med."},{"key":"2019111822504399100_B5","doi-asserted-by":"crossref","first-page":"4823","DOI":"10.1073\/pnas.82.14.4823","article-title":"Differentiation of normal marrow and HL60 cells induced by antithymocyte globulin.","volume":"82","author":"Hunter","year":"1985","journal-title":"Proc Natl Acad Sci U S A."},{"key":"2019111822504399100_B6","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1182\/blood.V68.3.712.712","article-title":"Biological and immunological characterization of ATG and ALG.","volume":"68","author":"Raefsky","year":"1986","journal-title":"Blood."},{"key":"2019111822504399100_B7","doi-asserted-by":"crossref","first-page":"534","DOI":"10.7326\/0003-4819-136-7-200204020-00011","article-title":"Acquired aplastic anemia.","volume":"136","author":"Young","year":"2002","journal-title":"Ann Intern Med."},{"key":"2019111822504399100_B8","doi-asserted-by":"crossref","first-page":"156","DOI":"10.7326\/0003-4819-137-3-200208060-00007","article-title":"Antithymocyte globulin for treatment of the bone marrow failure associated with myelodysplastic syndromes.","volume":"137","author":"Molldrem","year":"2002","journal-title":"Ann Intern Med."},{"key":"2019111822504399100_B9","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1046\/j.1365-2141.1997.4423249.x","article-title":"Antithymocyte globulin for patients with myelodysplastic syndrome.","volume":"99","author":"Molldrem","year":"1997","journal-title":"Br J Haematol."},{"key":"2019111822504399100_B10","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1182\/blood.V89.6.2079","article-title":"International scoring system for evaluating prognosis in myelodysplastic syndromes.","volume":"89","author":"Greenberg","year":"1997","journal-title":"Blood."},{"key":"2019111822504399100_B11","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1182\/blood.V100.5.1570.h81702001570_1570_1574","article-title":"HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome.","volume":"100","author":"Saunthararajah","year":"2002","journal-title":"Blood."},{"key":"2019111822504399100_B12","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S0037-1963(00)90027-1","article-title":"Myelodysplastic syndrome and aplastic anemia: distinct entities or diseases linked by a common pathophysiology?","volume":"37","author":"Barrett","year":"2000","journal-title":"Semin Hematol."},{"key":"2019111822504399100_B13"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/101\/6\/2156\/1261211\/h80603002156.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/101\/6\/2156\/1261211\/h80603002156.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T03:50:51Z","timestamp":1574135451000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/101\/6\/2156\/106481\/Antithymocyte-globulin-has-limited-efficacy-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,3,15]]},"references-count":13,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2003,3,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2002-09-2867","relation":{},"ISSN":["1528-0020","0006-4971"],"issn-type":[{"value":"1528-0020","type":"electronic"},{"value":"0006-4971","type":"print"}],"subject":[],"published":{"date-parts":[[2003,3,15]]}}}